152 related articles for article (PubMed ID: 7779709)
1. In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia.
Klumper E; Pieters R; den Boer ML; Huismans DR; Loonen AH; Veerman AJ
Br J Cancer; 1995 Jun; 71(6):1188-93. PubMed ID: 7779709
[TBL] [Abstract][Full Text] [Related]
2. In vitro cytotoxicity of mitoxantrone, daunorubicin and doxorubicin in untreated childhood acute leukemia.
Kaspers GL; Veerman AJ; Pieters R; van Zantwijk I; Klumper E; Hählen K; de Waal FC; van Wering ER
Leukemia; 1994 Jan; 8(1):24-9. PubMed ID: 8289494
[TBL] [Abstract][Full Text] [Related]
3. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.
Feig SA; Ames MM; Sather HN; Steinherz L; Reid JM; Trigg M; Pendergrass TW; Warkentin P; Gerber M; Leonard M; Bleyer WA; Harris RE
Med Pediatr Oncol; 1996 Dec; 27(6):505-14. PubMed ID: 8888809
[TBL] [Abstract][Full Text] [Related]
4. The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia.
Li X; Xu S; Tan Y; Chen J
Cochrane Database Syst Rev; 2015 Jun; (6):CD010432. PubMed ID: 26037486
[TBL] [Abstract][Full Text] [Related]
5. Relationship between the intracellular daunorubicin concentration, expression of major vault protein/lung resistance protein and resistance to anthracyclines in childhood acute lymphoblastic leukemia.
Den Boer ML; Pieters R; Kazemier KM; Janka-Schaub GE; Henze G; Veerman AJ
Leukemia; 1999 Dec; 13(12):2023-30. PubMed ID: 10602424
[TBL] [Abstract][Full Text] [Related]
6. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells.
Berman E; McBride M
Blood; 1992 Jun; 79(12):3267-73. PubMed ID: 1596567
[TBL] [Abstract][Full Text] [Related]
7. Role of anthracyclines in the treatment of adult acute lymphoblastic leukemia.
Bassan R; Lerede T; Rambaldi A; Barbui T
Acta Haematol; 1996; 95(3-4):188-92. PubMed ID: 8677741
[TBL] [Abstract][Full Text] [Related]
8. Different types of non-P-glycoprotein mediated multiple drug resistance in children with relapsed acute lymphoblastic leukaemia.
Pieters R; Hongo T; Loonen AH; Huismans DR; Broxterman HJ; Hählen K; Veerman AJ
Br J Cancer; 1992 May; 65(5):691-7. PubMed ID: 1350207
[TBL] [Abstract][Full Text] [Related]
9. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
Wadler S; Fuks JZ; Wiernik PH
J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
[TBL] [Abstract][Full Text] [Related]
10. Cross resistance relevance of the chemical structure of different anthracyclines in multidrug resistant cells.
Tapiero H; Nguyen-Ba G; Lampidis TJ
Pathol Biol (Paris); 1994 Apr; 42(4):328-37. PubMed ID: 7808786
[TBL] [Abstract][Full Text] [Related]
11. In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia.
Styczynski J; Pieters R; Huismans DR; Schuurhuis GJ; Wysocki M; Veerman AJ
Br J Haematol; 2000 Sep; 110(4):813-8. PubMed ID: 11054062
[TBL] [Abstract][Full Text] [Related]
12. The influence of intracellular idarubicin and daunorubicin levels on drug cytotoxicity in childhood acute leukemia.
Styczyński J; Wysocki M; Debski R; Kurylak A; Balwierz W; Rokicka-Milewska R; Matysiak M; Balcerska A; Kowalczyk J; Wachowiak J; Sońta-Jakimczyk D; Chybicka A
Acta Biochim Pol; 2002; 49(1):99-107. PubMed ID: 12136962
[TBL] [Abstract][Full Text] [Related]
13. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
Roovers DJ; van Vliet M; Bloem AC; Lokhorst HM
Leuk Res; 1999 Jun; 23(6):539-48. PubMed ID: 10374847
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase II alpha gene expression in childhood acute lymphoblastic leukemia.
Klumper E; Giaccone G; Pieters R; Broekema G; van Ark-Otte J; van Wering ER; Kaspers GJ; Veerman AJ
Leukemia; 1995 Oct; 9(10):1653-60. PubMed ID: 7564505
[TBL] [Abstract][Full Text] [Related]
15. Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance.
Lotfi K; Zackrisson AL; Peterson C
Cancer Lett; 2002 Apr; 178(2):141-9. PubMed ID: 11867198
[TBL] [Abstract][Full Text] [Related]
16. The role of idarubicin in adult acute lymphoblastic leukaemia: from drug resistance studies to clinical application.
Bassan R; Chiodini B; Lerede T; Torri V; Borleri G; Rambaldi A; Barbui T
Leuk Lymphoma; 1997 Dec; 26 Suppl 1():89-97. PubMed ID: 9570685
[TBL] [Abstract][Full Text] [Related]
17. Daunorubicin during delayed intensification decreases the incidence of infectious complications - a randomized comparison in trial CoALL 08-09.
Schramm F; Zimmermann M; Jorch N; Pekrun A; Borkhardt A; Imschweiler T; Christiansen H; Faber J; Feuchtinger T; Schmid I; Beron G; Horstmann MA; Escherich G
Leuk Lymphoma; 2019 Jan; 60(1):60-68. PubMed ID: 29966458
[TBL] [Abstract][Full Text] [Related]
18. Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study.
Koh KN; Im HJ; Kim H; Kang HJ; Park KD; Shin HY; Ahn HS; Lee JW; Yoo KH; Sung KW; Koo HH; Lim YT; Park JE; Park BK; Park HJ; Seo JJ
J Korean Med Sci; 2017 Apr; 32(4):642-649. PubMed ID: 28244291
[TBL] [Abstract][Full Text] [Related]
19. Anthracycline antibiotics induce acute renal tubular toxicity in children with cancer.
Bárdi E; Bobok I; V Oláh A; Kappelmayer J; Kiss C
Pathol Oncol Res; 2007; 13(3):249-53. PubMed ID: 17922055
[TBL] [Abstract][Full Text] [Related]
20. Use of the microculture kinetic assay of apoptosis to determine chemosensitivities of leukemias.
Kravtsov VD; Greer JP; Whitlock JA; Koury MJ
Blood; 1998 Aug; 92(3):968-80. PubMed ID: 9680366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]